SLC1A2

Across TCGA pan-cancer cohorts, SLC1A2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SLC1A2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC1A2 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC1A2 is over-expressed in tumor, although a few such as LUAD and KIRC show the opposite, repressed pattern.

LUAD, KIRC, and BRCA are the cancer types where SLC1A2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC1A2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.632	<.001	10	view →
KIRC	All	III,IV	−0.109	.001	8	view →
BRCA	All	II,III,IV	+0.675	<.001	6	view →
LUSC	Female	II,III,IV	−0.485	.001	6	view →
THCA	Male	All	−0.418	<.001	6	view →
KIRP	All	All	−0.130	<.001	6	view →
CHOL	All	II,III,IV	−3.635	<.001	5	view →
COAD	Male	II,III,IV	−0.168	.002	5	view →
KICH	All	All	+0.834	.002	4	view →
LIHC	Female	All	−1.358	<.001	3	view →
ESCA	All	All	−2.146	.002	2	view →
BLCA	Male	IV	−0.235	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SLC1A2–LUAD

Open the LUAD breakdown →